FGF23-Klotho axis in patients with rheumatoid arthritis
A. Alvarez-Cienfuegos1, L. Cantero-Nieto2, J. Garcia-Gomez3, G. Robledo4, M. González-Gay5, N. Ortego-Centeno6
- Department of Rheumatology, Hospital Vega-Baja, Alicante, Spain. email@example.com
- Department of Emergency, Hospital Santa Ana, Granada, Spain.
- Infectious Diseases Unit, Hospital General de Elche, Alicante, Spain.
- Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain.
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain. School of Medicine, University of Cantabria, Santander, Spain
- Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada; School of Medicine, University of Granada, Instituto de Investigación Biosanitaria, IBS, Granada, Spain.
2020 Vol.38, N°0 - PI 0050, PF 0057
We aimed to compare serum Klotho and fibroblast growth factor-23 (FGF-23) levels between rheumatoid arthritis (RA) patients and healthy controls. Possible association between FGF-23 and soluble Klotho with different characteristic of the disease as well as their potential role as surrogate markers of cardiovascular disease (CVD) were studied.
Sixty-three patients with RA recruited at Vega-Baja Hospital, Orihuela (Spain) from November 2016 to May 2018 and sixty-five age- and sex-matched healthy controls were included in this study. Serum Klotho and FGF-23 were analysed using ELISA.
Patients had higher serum levels of Klotho than healthy controls (p˂0.0001). They were positively associated with the presence of anticitrullinated peptide antibody and rheumatic factor (p<0.05). Klotho serum levels were higher in RA patients treated with biologic agents than in those undergoing conventional therapy (p=0.008). However, no association with carotid intima media thickness was found. Although no significant differences in serum FGF-23 levels between patients and controls were found (p=0.43), FGF-23 levels were positively associated with low-density lipoprotein (LDL-c) level (p<0.05) and smoking (p=0.008) in patients with RA.
The increased serum Klotho levels in RA patients, especially in those undergoing biologic therapy, may indicate a potential implication in the pathogenesis of the disease. Although levels of FGF-23 were related to LDL-c levels, the FGF-23-Klotho axis does not seem to be related to subclinical arteriosclerosis in RA.
PMID: 31025926 [PubMed]
Received: 02/01/2019 - Accepted : 11/03/2019 - In Press: 16/04/2019 - Published: 06/02/2020